Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.0.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Oct. 31, 2023
Segment Reporting Information [Line Items]      
Net loss $ (3,290) $ (2,354)  
Total operating costs and expenses 3,609 2,556  
Less non-cash share-based compensation (1,260) (1,063)  
Operating costs and expenses excluding non-cash share based compensation 2,349 1,493  
Total assets 25,372   $ 25,522
Cart Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Net loss (1,525) (911)  
Operating costs and expenses excluding non-cash share based compensation 1,128 598  
Total assets 12,124   7,523
Cancer Vaccines [Member]      
Segment Reporting Information [Line Items]      
Net loss (1,756) (958)  
Operating costs and expenses excluding non-cash share based compensation 1,213 588  
Total assets 13,162   17,215
Anti Viral Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Net loss (482)  
Operating costs and expenses excluding non-cash share based compensation 305  
Total assets   700
Other [Member]      
Segment Reporting Information [Line Items]      
Net loss (9) (3)  
Operating costs and expenses excluding non-cash share based compensation 8 $ 2  
Total assets $ 86   $ 84